Alkem Labs Q4FY26 Revenue Up 14.6% to ₹36,033 Million, EBITDA Grows 32.2%
Alkem Laboratories reported record EBITDA for FY26 and strong Q4FY26 results. Q4 revenue grew 14.6% YoY to ₹36,033 million, with EBITDA up 32.2% to ₹5,174 million. FY26 revenue increased 13.5% to ₹147,123 million, and EBITDA grew 19.6% to ₹30,052 million. Domestic sales rose 8.8% in Q4, while international sales saw robust growth, particularly in the US.
The announcement includes key financial highlights such as record EBITDA, significant revenue growth, and margin expansion, which are material factors for investors and will likely influence market perception and stock performance.
The company reported record EBITDA, strong revenue growth across domestic and international segments, and improved margins, indicating positive financial performance and operational efficiency.
Alkem Laboratories Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹36,033 million for Q4 FY26, marking a year-on-year growth of 14.6%. EBITDA for the quarter stood at ₹5,174 million, a 32.2% increase YoY, with an EBITDA margin of 14.4% compared to 12.4% in Q4 FY25. Profit After Tax (PAT) for the quarter saw a decline of 22.7% YoY to ₹2,365 million. For the full fiscal year FY26, total revenue from operations grew by 13.5% YoY to ₹147,123 million. EBITDA for FY26 was ₹30,052 million, up 19.6% YoY, resulting in an improved EBITDA margin of 20.4%. PAT for FY26 increased by 6.3% YoY to ₹23,018 million.
The domestic business reported Q4 FY26 sales of ₹23,245 million, an 8.8% YoY growth. The company outperformed the Indian Pharmaceutical Market (IPM) in the acute segment by 230 bps and the chronic segment by 250 bps, driven by strong performance in six key therapies. For FY26, domestic sales grew by 9.7% YoY to ₹98,514 million, with the company outperforming IPM by 20 bps overall.
The international business also showed robust growth. US sales in Q4 FY26 increased by 26.2% YoY to ₹7,681 million, contributing 21.7% to total sales. Non-US sales grew by 24.1% YoY to ₹4,543 million. For FY26, US sales grew by 20.3% YoY to ₹29,845 million, and Non-US sales grew by 26.7% YoY to ₹16,964 million. During FY26, the company filed 192 ANDAs and received 167 approvals in the US.
Commenting on the results, Dr. Vikas Gupta, CEO of Alkem, stated, "We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26."
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.